BioCryst Pharmaceuticals Statistics
Share Statistics
BioCryst Pharmaceuticals has 209.25M
shares outstanding. The number of shares has increased by 1.25%
in one year.
| Shares Outstanding | 209.25M |
| Shares Change (YoY) | 1.25% |
| Shares Change (QoQ) | 0.88% |
| Owned by Institutions (%) | 81.03% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 679 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 18.3M, so 8.74% of the outstanding
shares have been sold short.
| Short Interest | 18.3M |
| Short % of Shares Out | 8.74% |
| Short % of Float | 8.78% |
| Short Ratio (days to cover) | 4.78 |
Valuation Ratios
The PE ratio is -17.49 and the forward
PE ratio is 44.35.
BioCryst Pharmaceuticals's PEG ratio is
0.28.
| PE Ratio | -17.49 |
| Forward PE | 44.35 |
| PS Ratio | 3.45 |
| Forward PS | 2.3 |
| PB Ratio | -3.27 |
| P/FCF Ratio | -29.25 |
| PEG Ratio | 0.28 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for BioCryst Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63,
with a Debt / Equity ratio of -1.7.
| Current Ratio | 2.63 |
| Quick Ratio | 2.58 |
| Debt / Equity | -1.7 |
| Debt / EBITDA | 63.14 |
| Debt / FCF | -15.22 |
| Interest Coverage | -0.03 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $777,089.66 |
| Profits Per Employee | $-153,243.1 |
| Employee Count | 580 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.52 |
Taxes
| Income Tax | 1.93M |
| Effective Tax Rate | -2.22% |
Stock Price Statistics
The stock price has increased by 63.06% in the
last 52 weeks. The beta is 1.07, so BioCryst Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | 63.06% |
| 50-Day Moving Average | 8.15 |
| 200-Day Moving Average | 7.92 |
| Relative Strength Index (RSI) | 64.72 |
| Average Volume (20 Days) | 4,716,908 |
Income Statement
In the last 12 months, BioCryst Pharmaceuticals had revenue of 450.71M
and earned -88.88M
in profits. Earnings per share was -0.43.
| Revenue | 450.71M |
| Gross Profit | 438.44M |
| Operating Income | -2.54M |
| Net Income | -88.88M |
| EBITDA | 12.81M |
| EBIT | 11.56M |
| Earnings Per Share (EPS) | -0.43 |
Full Income StatementBalance Sheet
The company has 104.71M in cash and 808.74M in
debt, giving a net cash position of -704.03M.
| Cash & Cash Equivalents | 104.71M |
| Total Debt | 808.74M |
| Net Cash | -704.03M |
| Retained Earnings | -1.77B |
| Total Assets | 490.42M |
| Working Capital | 261.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -52.02M
and capital expenditures 0, giving a free cash flow of -53.14M.
| Operating Cash Flow | -52.02M |
| Capital Expenditures | n/a |
| Free Cash Flow | -53.14M |
| FCF Per Share | -0.26 |
Full Cash Flow StatementMargins
Gross margin is 97.28%, with operating and profit margins of -0.56% and -19.72%.
| Gross Margin | 97.28% |
| Operating Margin | -0.56% |
| Pretax Margin | -19.29% |
| Profit Margin | -19.72% |
| EBITDA Margin | 2.84% |
| EBIT Margin | -0.56% |
| FCF Margin | -11.79% |
